Fibrinolytic Therapy Market, By Drug Type (Alteplase, Reteplase, Tenecteplase, Streptokinase, Anistreplase, Urokinase), By Indication (Acute Ischemic Stroke, Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, Peripheral Arterial Thrombosis, Other Thrombotic Conditions), By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), By Administration (Intravenous (IV), Intra-arterial (IA)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Patient Age (Adult Patients, Pediatric Patients), By Packaging Type (Vials, Ampoules, Pre-filled Syringes), By Application (Emergency Care, Interventional Cardiology, Thrombosis Treatment, Others), By Dosage Form (Lyophilized Powder for Reconstitution, Solution for Injection), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
Fibrinolytic therapy is used to dissolve blood clots that cause heart attacks or strokes. It is a lifesaving treatment, but it doesn't address underlying health problems that can lead to other serious diseases and conditions. Thrombolysis is usually given through an IV line. It is used when symptoms of a stroke or heart attack are present and not responding to other treatments, like anticoagulants and steroid medications. It can be given at home or in a hospital. Tissue plasminogen activator or alteplase, a drug that breaks down fibrin and other substances that create clots in the body, is most commonly used for thrombolysis. The drug tenecteplase is also effective in some patients, and it can be given by mouth.
Market Dynamic:
The increasing incidences of trauma and road accidents are driving the demand for antifibrinolytic drugs, which in turn is fuelling fibrinolytic therapy market growth. The growing use of these drugs in oral bleeding treatments, mainly for menorrhagia (heavy menstrual flow) is again anticipated to bolster the market growth further. Moreover, rising incidences of severe road accidents and trauma is creating demand for anti-fibrinolytic drugs, thereby propelling market growth. Furthermore, the rising adoption of these drugs for treating hemophilia and other conditions such as platelet dysfunctions, Von Willebrand diseases and haemophilia A and B is further bolstering the market growth
However, the high price of these drugs is a key factor that can hinder the industry’s growth.
Key features of the study:
This report provides in-depth analysis of the global fibrinolytic therapy market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global fibrinolytic therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Genentech, Inc. (Roche), Bayer AG, Boehringer Ingelheim International GmbH, Pfizer Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca PLC, Johnson & Johnson Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global fibrinolytic therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibrinolytic therapy market
Detailed Segmentation:
Fibrinolytic Therapy Market, By Drug Type:
Alteplase
Reteplase
Tenecteplase
Streptokinase
Anistreplase
Urokinase
Fibrinolytic Therapy Market, By Indication:
Acute Ischemic Stroke
Acute Myocardial Infarction
Deep Vein Thrombosis
Pulmonary Embolism
Peripheral Arterial Thrombosis
Other Thrombotic Conditions
Fibrinolytic Therapy Market, By End User:
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
Fibrinolytic Therapy Market, By Administration:
Intravenous (IV)
Intra-arterial (IA)
Fibrinolytic Therapy Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Fibrinolytic Therapy Market, By Patient Age:
Adult Patients
Pediatric Patients
Fibrinolytic Therapy Market, By Packaging Type:
Vials
Ampoules
Pre-filled Syringes
Fibrinolytic Therapy Market, By Application:
Emergency Care
Interventional Cardiology
Thrombosis Treatment
Others
Fibrinolytic Therapy Market, By Dosage Form:
Lyophilized Powder for Reconstitution
Solution for Injection
Fibrinolytic Therapy Market, By Geography:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Company Profile
Genentech, Inc. (Roche)
Bayer AG
Boehringer Ingelheim International GmbH
Pfizer Inc.
Bristol Myers Squibb Company
Novartis AG
AstraZeneca PLC
Johnson & Johnson
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Abbott Laboratories
Mallinckrodt Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation